Press Releases Aprea Therapeutics, Inc.

Equities

APRE

US03836J2015

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.2 ^USD	-2.80%		-2.80%	+10.64%

Apr. 10	Aprea Therapeutics, Inc. Announces Presentations on Its Next Generation Wee1 Inhibitor, Apr-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024	CI
Mar. 27	Wedbush Raises Aprea Therapeutics' PT to $11 From $9 After Layering In Recent Financing, Maintains Outperform Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024	Apr. 10	AQ
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	Mar. 26	AQ
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million	Mar. 11	AQ
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers	Mar. 11	AQ
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024	Mar. 05	AQ
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor	Feb. 06	AQ
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024	Jan. 30	AQ
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024	Jan. 04	AQ
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update	Nov. 09	AQ
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways	23-10-24	AQ
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio	23-10-16	AQ
Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	23-09-19	AQ
Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors	23-09-11	AQ
Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	23-09-06	AQ
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman	23-08-24	AQ
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations	23-08-10	AQ
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference	23-06-14	AQ
Aprea Therapeutics to Present at BIO International Convention	23-05-30	AQ
APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)	23-05-15	AQ
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations	23-05-15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Aprea Therapeutics, Inc.

Equities

APRE

US03836J2015

Press Releases

Filters